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A gastrointestinal–renal natriuretic signaling axis has been
proposed to regulate sodium excretion in response to acute
sodium ingestion. Such an axis is thought to be regulated by
a gastrointestinal sodium sensor coupled to the activation/
release of a natriuretic signal and could have important
clinical and scientific implications. Here we systematically
tested for this putative axis and the potential involvement of
the gastrointestinal-derived natriuretic prohormones
prouroguanylin and proguanylin in 15 healthy volunteers.
There was no difference in sodium excretion following
equivalent oral or intravenous sodium loads during either
high- or low-sodium diets. Furthermore, serum
concentrations of prouroguanylin and proguanylin did not
increase, did not differ following oral or intravenous sodium,
and did not correlate with sodium excretion. Thus, our results
do not support an acute gastrointestinal–renal natriuretic axis
or a central role for prouroguanylin or proguanylin in
humans. If such an axis does exist, it is not characterized by a
significant difference in the pattern of sodium excretion
following either an oral or intravenous sodium load.
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There has been renewed interest in a putative rapid-acting
gastrointestinal (GI)–renal natriuretic signaling axis, which
may have a key role in the acute regulation of renal sodium
excretion in response to sodium ingestion.1,2 The proposed
mechanism of this natriuretic axis is that a dietary sodium
load is detected by a GI sodium sensor that is coupled to the
activation or release of a natriuretic signal, which in turn acts
on the kidney to increase sodium excretion. Such an axis
could have major clinical and scientific implications for
sodium handling in health and disease.
Support for this GI–renal natriuretic axis arises primarily
from the observation3,4 that an equivalent sodium load is
more rapidly excreted when given orally than when given
intravenously. On the basis of this observation, it was
suggested that the GI tract has the capacity to detect ingested
sodium and subsequently release a natriuretic effector
hormone into the circulation. Nevertheless, whether a
GI–renal natriuretic axis exists in humans has not been
firmly established. Furthermore, there is a lack of follow-up
studies specifically conducted to confirm these important
early observations. In addition, these early studies of oral
versus intravenous (IV) sodium handling were conducted
only during low sodium intake.
There has been recent intense interest in the small guanylyl
cyclase–activating natriuretic peptide uroguanylin (UGN)
and its inactive propeptide prouroguanylin (pro-UGN) as the
leading candidate effector molecules for a putative GI–na-
triuretic axis linking dietary sodium intake to acute changes
in sodium excretion.1,2,5–31 The proposed mechanism for this
axis is that the inactive prohormone pro-UGN is produced
and stored in intestinal mucosa and is released into the
circulation in response to sodium ingestion. Pro-UGN then
circulates along with some preformed UGN11,13 and is
converted to its active form UGN in the kidney,5,6 where it
acts to directly promote sodium excretion. There is a similar
mechanism that has been proposed for the prohormone
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proguanylin (pro-GN) and its corresponding active hormone
guanylin (GN), although pro-GN and GN have been less well
studied.8,9,17,26–28
Nevertheless, although there is some experimental support
that pro-UGN is secreted from intestinal mucosa under the
influence of dietary sodium chloride, it has not yet been
established whether serum pro-UGN concentration increases
in response to a dietary sodium chloride load and whether
the pro-UGN levels indeed correlate with sodium excretion
in humans.
We sought to systematically investigate the existence in
humans of the putative rapid-acting GI–renal natriuretic
signaling axis and the potential role(s) of the GI-derived
natriuretic prohormones pro-UGN and pro-GN as mediators
of this axis. The specific objectives of this randomized
experimental clinical trial conducted in healthy young human
volunteers in a monitored inpatient clinical pharmacology
research unit under both low and high sodium intakes were as
follows: (1) to determine whether an oral sodium load is
excreted more rapidly than sodium given intravenously
during steady-state maintenance with either low- or high-
sodium diets, thus supporting the existence of a GI–renal
natriuretic axis; (2) to determine whether serum concentra-
tions of pro-UGN and the less well-characterized proguanylin
(pro-GN) increase acutely in response to a sodium load; (3)
to determine whether the response in pro-UGN and pro-GN
concentrations is greater following oral versus intravenous
administration, thus supporting a GI-pro-UGN signaling axis;
and (4) to determine whether changes in pro-UGN and pro-
GN concentrations correlate with renal sodium excretion.
RESULTS
Baseline and demographic characteristics
Twenty-three potential subjects were screened. Eight did not
qualify for the study. Two potential subjects had elevated liver
enzymes at screening, one had elevated potassium and
triglycerides, one had estimated Ccr o100 ml/min, and three
indicated after screening that they would not be able to comply
with the extended inpatient stays and dietary restrictions
(Table 1).
Fifteen participants were enrolled and completed the first
inpatient period and both sodium handling studies (Table 1).
Eleven completed both phases including all four sodium
handling studies. Of the 15 enrolled, 9 were men and 6 were
women. The mean (s.d.) age of the group was 26.5 (2.9)
years. The mean (s.d.) body mass index was 25.9 (4.1), the
Cockroft–Gault-estimated glomerular filtration rate was
131.7 (32.1) ml/min, and the modification of diet in renal
disease–estimated glomerular filtration rate was 116.5 (17.5)
ml/min. The mean (s.d.) sodium excretion after 5 days of low
sodium intake was 21 (9) mmol per 24 h and during the
high-sodium period was 151 (43) mmol per 24 h. We
observed a trend to an inverse correlation of basal urinary
sodium excretion (UnaV) with aldosterone concentration but
no correlation with either pro-UGN or pro-GN.
Sodium excretion in response to an IV versus oral sodium load
Cumulative and hourly sodium excretion for the entire 24-h
acute sodium handling period for both the low- and high-
sodium periods are shown in Figure 1a and b. Figure 1c and d
display the first 6 h of Figure 1a and b, respectively.
Cumulative sodium excretion for the entire 24-h period did
not differ between the IV and oral administration studies for
either the low sodium or the high-sodium periods. Similarly,
neither hourly sodium excretion nor cumulative sodium
excretion was significantly higher following oral administra-
tion at interim points of either the low-sodium or the high-
sodium periods.
Individual sodium excretion curves
The individual sodium excretion curves for the 15 subjects
who completed period 1 and the 11 subjects who completed
both periods are shown in Figure 2. In reviewing the
individual subject data, there appeared to exist little evidence
for subjects to manifest a higher natriuretic response to oral
versus IV administration.
Table 1 | Baseline and demographic characteristics
Age (years) Gender (M/F) Race BMI (kg/m2) SBP (mmHg) DBP (mmHg)
C–G eGFR
(ml/min)
MDRD
eGFR (ml/min)
1 21 M C 28.4 116 68 203 150
2 29 M C 22.5 126 72 105 98
3 29 F C 21.7 104 73 107 103
4 22 M C 31.2 122 76 160 115
5 23 F B 31.9 119 82 165 129
6 26 M C 24.0 120 62 104 90
7 29 M B 31.5 120 84 147 124
8 24 M C 22.9 122 74 119 89
9 30 M C 31.9 124 72 180 121
10 27 F C 21.8 108 70 106 138
11 30 M C 28.7 126 76 131 121
12 28 F C 23.0 113 79 112 110
13 25 F C 23.9 106 73 107 111
14 28 M C 21.6 110 68 101 115
15 27 F C 23.0 93 67 128 135
Abbreviations: B, Black; BMI, body mass index; C, Caucasian; C–G eGFR, Cockroft–Gault-estimated glomerular filtration rate; DBP, diastolic blood pressure; F, Female; M, male;
MDRD eGFR, Modification of Diet in Renal Disease equation estimated glomerular filtration rate; SBP, systolic blood pressure.
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Aldosterone concentration response to oral versus IV sodium
Aldosterone concentration (ng/dl) response to oral versus
IV sodium administration during the 6-h acute sodium
handling study for both the high- and low-sodium periods
is shown in Figure 3. Aldosterone concentration did not
differ between oral and IV administration for either study
period.
Serum pro-UGN and pro-GN concentrations in response to
acute IV versus oral sodium load
The acute responses of pro-UGN and pro-GN concentrations
to sodium administration during the 6-h acute sodium
handling study for both the high-and low-sodium periods are
shown in Figure 4a and b. During the low-sodium diet
condition, serum pro-UGN concentration at 60 min post
sodium administration had declined to 2.4 ng/ml with IV
and 2.2 ng/ml with oral administration (Po0.01) and was
not significantly different from baseline value by the
midpoint of hour 6. During the high-sodium period,
serum pro-UGN concentration at 60 min post sodium
administration had declined to 2.1 with IV and 2.2 with
oral administration (Po0.001) and remained depressed
throughout the entire 6-h period. Pro-GN concentration
did not change significantly in response to either IV or oral
sodium administration for either the low- or high-sodium
intake periods.
Correlation of fall in pro-UGN with sodium excretion
As secondary analysis, we investigated the relationship
between pro-UGN concentration and sodium excretion via
the Spearman correlation between the drop in pro-UGN over
the first 90 min and cumulative sodium excretion for the 6-h
acute sodium handling study (see Figure 5), and did not
observe evidence of a relationship (IV/high diet: r¼ 0.1.
(P¼ 0.78), oral/high diet: r¼ 0.21 (P¼ 0.54), IV/low diet:
r¼ 0.07 (P¼ 0.79), oral/low diet: r¼ 0.21 (P¼ 0.44)). In
addition, we further investigated the joint evolution of
pro-UGN concentration and UnaV for oral administration
(high diet) via the correlation of pro-UGN and UnaV
slope random effects within a multivariate mixed-effects
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Figure 1 | Sodium excretion in response to an IV versus oral sodium load (Mean (s.e.m.)). IV, intravenous; cUnaV, cumulative urine
sodium excretion; UnaV, urinary sodium excretion.
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model.32,33 This correlation was 0.73 and the likelihood
ratio test for correlated random effects between pro-UGN
concentration and UnaV yielded P¼ 0.18, thereby not
providing strong evidence for the joint evolution hypothesis.
In summary, we did not find strong evidence for a correlation
between the decrease in pro-UGN concentration and the
increase in sodium excretion.
Blood pressure and creatinine clearance
Systolic and diastolic blood pressure versus time during the
sodium handling study is shown in Figure 6. Blood pressure
did not change significantly following the saline challenge.
Creatinine clearance (Ccr, ml/min) is shown in Figure 7. On
the 200 mmol/day diet, Ccr increased following the saline
challenge but did not differ between oral and IV sodium
administration. The increase in Ccr occurred at roughly the
same time point as the drop in pro-UGN concentration.
Thus, an increase in glomerular filtration rate could have
possibly resulted in increased filtration of pro-UGN, although
this drop was not observed for pro-GN.
DISCUSSION
We found no difference in the cumulative or hourly
natriuretic response to oral versus IV sodium administration
during either a standard 30 mmol Na diet or a standard
200 mmol Na diet in healthy human volunteers. Therefore,
our results do not confirm the earlier findings of a more
rapid sodium excretion following oral versus IV administra-
tion and do not support the existence of an acute GI–renal
natriuretic signaling axis. Our study was comparable to an
earlier study,4 which maintained subjects on the standardized
diet for 4 days before the sodium handling study that was
conducted on day 5. In our study, subjects were housed in our
clinical pharmacology research unit on the controlled diet for
5 days before the first Na handling study, which was conducted
on day 6. Our subjects then continued the controlled diet for 3
more days as a recovery period before the second sodium
handling study, which was conducted on day 10.
It can be argued that the finding of equal excretion
following oral versus IV sodium administration does not
entirely exclude the existence of such an axis. The IV admini-
stration would theoretically result in a nearly immediate
expansion of the extracellular fluid volume and stimulation
of rapid-acting natriuretic mechanisms. Oral administration,
however, would require absorption across the GI mucosa, and
travel across the GI vascular bed to the central veins before
expanding the extracellular volume. Such a delay could
theoretically manifest as a slower excretion. The finding of equal
rates of excretion may therefore suggest that such an axis may
exist. Nevertheless, we were unable to confirm the existence
of this axis using our rigorous sodium challenge protocol.
Our results do not substantiate the long-held notion that
an oral saline load is significantly more rapidly excreted than
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Figure 2 | Individual sodium excretion curves. (a) 30mmol Na diet. (b) 200mmol Na diet. IV, intravenous; cUnaV, cumulative sodium
excretion rate.
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Figure 3 |Aldosterone response to oral versus intravenous (IV)
sodium.
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the equivalent IV load. The earlier studies found that salt-
depleted individuals consuming a 10-mmol sodium diet who
were given 100 mmol oral sodium chloride had higher
cumulative sodium excretion over 24 h than individuals
given the same amount of sodium intravenously. However,
differences between oral and IV administration were small
after 2 h and became increasingly more pronounced with
each time interval over the ensuing 24-h period. The
difference between cumulative UnaV paradoxically becoming
greater after 8–12 h does not seem consistent with an acute,
rapid-acting signaling mechanism in which the difference
would be most pronounced immediately or shortly after the
sodium load.
We performed the oral versus IV sodium handling studies
during the same admission period under exactly the same
dietary conditions. The earlier study separated the sodium
handling experiments by an outpatient period and was
conducted only during low (10 mmol per 24 h) sodium
intake. Conducting sodium handling studies only during a
low basal sodium intake is problematic given that under these
conditions natriuretic mechanisms would be blunted. Our
sodium handling studies were conducted under both low
(30 mmol) and high (200 mmol) sodium intakes that were
selected to represent the spectrum of physiological sodium
intakes. We selected 30 mmol rather than 10 mmol because it
represents the extreme lower limit of sodium intake in a
reasonable physiological range. The average urinary excretion
of sodium after 5 days suggests an average intake of 21 (9)
mmol per 24 h. Neither the high nor low dietary sodium
confinement condition revealed a difference between oral and
IV sodium administration. Consistent with the earlier
experiments, however, serial aldosterone concentrations did
not differ regardless of whether the sodium load was given
orally or intravenously.
Although the early studies showed a marked difference
between the rates of sodium excretion following oral versus
IV sodium, and some follow-up studies support these
findings,32 other studies did not always find such a
difference.33 Therefore, the existence of this axis has been
somewhat controversial.1 We should also point out that our
negative findings do not disprove the existence of a GI–renal
sodium axis. The GI tract may indeed detect changes in
sodium intake, but our investigation did not find that this
sensor manifests as a difference in the natriuretic response to
oral versus IV sodium. It should be mentioned that
aldosterone concentration has a diurnal variation, generally
highest in the morning and falling throughout the day and
night.34 There is little data, however, on the diurnal variation
in pro-UGN and pro-GN,29,35 although one study suggests
that levels are highest in humans in the morning.29
Basal aldosterone, pro-GN, and pro-UGN in our study
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demonstrated inter-subject variation consistent with existing
data (Figures 3 and 4a, b).
To our knowledge, this was the first study of changes in
pro-UGN and pro-GN concentrations in response to
sodium loading in humans. By comparing IV versus oral
sodium, we sought to differentiate whether there was a
GI sensor causing pro-UGN and pro-GN release. We did
not find evidence of such a release mechanism. On the
contrary, we found that pro-UGN concentrations decreased in
response to both oral and IV sodium administration. This
decrease could possibly reflect increased glomerular filtration
of pro-UGN and intra-renal conversion to UGN. Never-
theless, the reduction in pro-UGN was observed equally in
response to both IV and oral sodium. Our secondary
statistical analysis did not find evidence for a correlation
between the decrease in pro-UGN concentration and
sodium excretion.
Although our data do not support the hypothesis that an
ingested sodium load leads to the acute release of pro-UGN via
a GI-sensing mechanism, there is a long line of experimental
evidence supporting a substantial natriuretic effect of UGN.20–25
Moreover, disruption of endogenous UGN in mice results in
impaired excretion of oral sodium and hypertension.25
Nevertheless, in our randomized physiological study, we
did not find a difference in sodium excretion or changes in
pro-UGN or pro-GN concentrations in response to oral
versus IV sodium administration. Furthermore, we did not
observe an increase in pro-UGN or pro-GN concentrations in
response to either oral or IV sodium. These observations
provide evidence that the role of the pro-UGN/UGN system
in sodium balance may be more complex than the existing
leading hypotheses have indicated. In fact, we observed a
decrease in pro-UGN (but not pro-GN) concentration in
response to both oral and IV sodium.
Our randomized study, conducted in an inpatient clinical
pharmacology unit under close dietary control, provides key data
that help clarify scientifically and clinically important questions
regarding sodium metabolism in humans. Our results suggest
that if a GI–renal sodium axis does indeed exist, this axis does
not manifest as a significant difference in the pattern of sodium
excretion following a sodium load administered either orally
or intravenously. Moreover, this axis does not appear to be
mediated via increased release of pro-UGN or pro-GN.
MATERIALS AND METHODS
In this randomized physiological clinical trial, we determined
stimulated hourly and cumulative renal sodium excretion following
an oral sodium chloride challenge of 102.6 mmol versus an IV
sodium chloride challenge of 102.6 mmol in healthy volunteers. In
addition, we simultaneously determined the stimulated hourly pro-
UGN and pro-GN serum concentrations. These determinations were
made both during a standard low-sodium diet (30 mmol/day Na,
60 mmol/day K) and while receiving a standard high-sodium diet
(200 mmol/day Na, 60 mmol/day K). The rationale for this design
was that if a GI–renal natriuretic axis existed, sodium excretion
would be greater with oral than with IV administration. In addition,
if pro-UGN release is the mediator of this axis, we would anticipate
greater release of pro-UGN with oral than IV sodium. We further
hypothesized that these findings would be augmented on a high
versus a low sodium intake.
Primary end points
(1) Hourly (UnaV, mmol/h) and cumulative sodium excretion rates
(cUnaV, mmol) at baseline and following an oral versus an IV
102.6 mmol Na challenge during 30 mmol/day and 200 mmol/
day sodium diets.
(2) Hourly pro-UGN and pro-GN serum concentrations at baseline
and following an oral versus an IV 102.6 mmol Na challenge
during 30 mmol/day and 200 mmol/day sodium diets.
Secondary end points
(1) Hourly sodium excretion rate (UnaV, mmol/h) following an
oral versus an IV 102.6 mmol Na challenge during 30 mmol/day
and 200 mmol/day sodium diets.
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(2) Hourly aldosterone concentration (ng/dl) following an oral
versus an IV 102.6 mmol Na challenge during 30 mmol/day and
200 mmol/day sodium diets.
Study participants
The study was conducted by the Principal Investigator and study
team in accordance with the guidelines of the University of Miami
Human Subjects Research Office (Institutional Review Board) and
the Principles of the Declaration of Helsinki. Written informed
consent was obtained by study coordinators directly from all
participants before their entry into the study and before initiating
any study procedures. Subjects were recruited from a large database
of healthy volunteers and were eligible if they were between the ages
of 20 and 30 years and had no significant medical history. Qualified
participants had a normal physical examination, blood pressure
o130/80, and normal laboratory evaluation including a Cockroft–-
Gault-estimated glomerular filtration rate 4100 ml/min.
Study design and overview
This study consisted of a screening and eligibility visit followed by
two sequential 10-day confinement periods in the Clinical
Pharmacology Research Unit (CPRU) at the University of Miami.
The confinement periods were separated by an outpatient period of
at least 1 week, during which the study participants consumed their
usual diet. During the first 10-day confinement period, the
participants received a 30-mmol sodium 60-mmol K diet. During
the second 10-day confinement period, the participants received a
200-mmol sodium 60-mmol K diet. After diet stabilization during
confinement days 1–5, two 24-h sodium handling studies, one with
IV sodium load and the other with oral sodium load, were
conducted in random order on days 6 and 10. Meals were identical
and consumed at exactly the same times on days 6 and 10 of each
diet period during the 24-h sodium handling study. In addition,
meals were identical on days 3 and 7; 4 and 8; and 5 and 9.
Sodium handling study procedure for days 6 and 10
of each diet period
Each participant fasted overnight from 2200 hours of the previous
night except for ad libitum water intake. At approximately 0630
hours, two 500-ml water loads were followed directly by a 2-h
baseline control urine collection. At the midpoint of the 2-h baseline
urine collection, blood was taken to analyze pro-UGN, pro-GN,
creatinine, sodium, potassium, and aldosterone concentrations.
Urine volume for this 2-h period was recorded and samples analyzed
for creatinine, sodium, and potassium.
Following the 2-h baseline control urine collection, participants
received one of the following two experimental test procedures in
random order:
(1) 102.6 mmol oral sodium as sodium chloride tablets adminis-
tered over a 10–15-min period with 240 ml of sugar-free diet soft
drink and an additional 200 ml water.
(2) 102.6 mmol IV sodium as 3% saline (513 mmol/l) administered
over a 10–15-min period also with 240 ml of sugar-free diet soft
drink.
Following the NaCl load administration, diuresis was sustained
by hourly administration of 200 ml of water given at the beginning
of each of 6-hourly urine collection periods. Urine samples for
creatinine, sodium, and potassium were collected for six additional
1-h periods. These periods terminated at 60, 120, 180, 240, 300, and
360 min following the administration of the sodium load. Following
the hour 6 urine collection, urine was collected and volume recorded
at intervals 6–8 h, 8–12 h, and 12–24 h. Blood was taken at 15, 30, 45,
60, 90, 150, 210, 270, and 330 min following the sodium load for
pro-UGN, pro-GN, creatinine, sodium, potassium, and aldosterone
concentrations.
Safety monitoring
The study participants were monitored closely in the locked,
secured, inpatient CPRU of the Division of Clinical Pharmacology
for signs of volume overload. Furosemide 20 mg ampoules for IV
administration were readily available on site in case of acute volume
overload.
Analytical methods
Pro-UGN and pro-GN concentrations. Samples for pro-UGN
and pro-GN were collected in serum separator tubes and centrifuged
immediately in a refrigerated centrifuge. They were frozen and
stored at 20 1C. Samples were analyzed within 1–2 weeks of being
drawn. Concentrations of pro-UGN (ng/ml) and pro-GN (ng/ml)
were determined in the serum samples using the Human
Prouroguanylin enzyme-linked immunosorbent assay (ELISA)
Immunoassay (RD191069200R, Biovendor, Modrice, Czech Republic)
and the Human Proguanylin ELISA Immunoassay (RD191046100R,
Biovendor) according to their assay directions. In brief, pro-UGN or
pro-GN ELISA standards, quality controls, and serum samples are
incubated in the wells of microtitration plates that have been coated
with anti-pro-UGN or anti-pro-GN antibodies. After washing the
wells thoroughly, biotin-labeled polyclonal anti-pro-UGN or anti-
pro-GN antibodies are added to the wells and incubated for 1 h. The
wells are washed and then a solution containing a conjugate of
streptavidin–horseradish peroxidase is added. Following 30 min of
incubation, the wells are washed and then the substrate, H2O2–
tetramethybenzidine, is added and the resulting product is measured
450 nm in a plate reader. Standard curves for authentic pro-UGN
and pro-GN are constructed according to the manufacturer’s
instructions.
Aldosterone concentration
Aldosterone concentration (ng/dl) was determined by coated-tube
radioimmunoassay.
Statistical methods
A sample size of 15 study participants allows the detection of a 1 s.d.
difference (oral versus IV; estimated 1.8 mmol) in mean hour 4 and
hour 6 cUnaV with a power of 0.90 and family-wise alpha 0.05
(each end point separately powered at alpha¼ 0.025). A power of
0.80 is achieved under these assumptions with a sample size
of 11 participants. Considering the possibility for subject with-
drawals, a conservative enrollment was considered to be 15 subjects.
A sample size of eight subjects was used in a previous study of Na
handling,3,4 yielding a large difference between oral and IV sodium
administration.
Summary statistics were calculated for demographic, clinical,
blood pressure, and biochemical measures. Differences in renal
sodium handling between the two interventions on both high and
low sodium intakes were detected using a paired t-test, along with
bootstrap confidence intervals. As secondary analysis, we investi-
gated the relationship between pro-UGN and sodium excretion in
response to sodium administration via the Spearman correlation
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between the drop in pro-UGN over the first 90 min and the cumu-
lative sodium excretion for the 6-h acute sodium handling study.
Multivariate mixed-effects models were also used to assess the joint
evolution of pro-UGN and pro-GN via correlation of slope random
effects.36–38 All statistical analyses were performed with R statistical
software, and the nlme R package was used to estimate multivariate
mixed-effects models via restricted maximum likelihood.39,40
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